Dependence receptors - the dark side awakens

The FEBS Journal
Ana-Maria Negulescu, Patrick Mehlen

Abstract

Transmembrane receptors are usually seen as on and off switches: when the specific ligand is bound, the receptor is on and transduces a downstream signal, whereas when the ligand is absent, the receptor is off. Over the last two decades several reports have argued for an alternative view where some receptors, depending on the context, will be active both in the presence and in the absence of ligand, being sort of onA and onB switch rather than on and off. These receptors have been named dependence receptors (DR) and they share the ability to actively trigger cell death when unbound by their respective ligands. DRs have been shown to be important guardians of tissue homeostasis. In pathological settings such as cancer, DRs are seen as tumour suppressors and a clinical trial is ongoing to assay whether these DRs can be used to provide clinical benefit by triggering cancer cell death. In this review we are reviewing this functional family of receptors and underlying their promising potential for targeted therapy against cancer.

References

Apr 14, 1989·Science·B VogelsteinR White
Sep 1, 1988·The New England Journal of Medicine·B VogelsteinJ L Bos
Jan 1, 1989·Molecular and Cellular Biology·D Martin-ZancaM Barbacid
Jul 28, 1994·The New England Journal of Medicine·J JenS R Hamilton
Jul 16, 1993·Science·S RabizadehD E Bredesen
Jan 1, 1997·Journal of Neuro-oncology·G M BrodeurA E Evans
Apr 18, 1997·The Journal of Biological Chemistry·T R BilderbackR T Dobrowsky
Jun 11, 1997·International Journal of Cancer. Journal International Du Cancer·D J EastyD C Bennett
Feb 14, 1998·Nature Genetics·S R KnezevichP H Sorensen
Mar 28, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D J YamashiroG M Brodeur
Aug 28, 1998·Science·N A Thornberry, Y Lazebnik
Apr 14, 1999·Cell Death and Differentiation·P A Barker
Apr 14, 1999·Cell Death and Differentiation·D E BredesenS Rabizadeh
May 23, 2000·Journal of Neuroscience Research·J J WangD E Bredesen
Mar 15, 2001·Proceedings of the National Academy of Sciences of the United States of America·C ForcetP Mehlen
Apr 17, 2001·Journal of Molecular Neuroscience : MN·S RabizadehD E Bredesen
Jun 2, 2001·The EMBO Journal·F LlambiP Mehlen
Oct 2, 2001·Cancer Letters·C Wicking, E McGlinn
Oct 5, 2001·Trends in Genetics : TIG·S ManiéM Billaud
Oct 31, 2001·The Journal of Cell Biology·D G StupackD A Cheresh
May 11, 2002·Nature Reviews. Cancer·Michael KarinZhi-Wei Li
Feb 25, 2003·The Journal of Biological Chemistry·Megan E WilliamsLindsay Hinck
Feb 25, 2003·Nature Cell Biology·Chizu TanikawaHirofumi Arakawa
Mar 26, 2003·Proceedings of the National Academy of Sciences of the United States of America·Karine ThiebaultPatrick Mehlen
Apr 19, 2003·The EMBO Journal·Haruhisa HiguchiMasaya Tohyama
Aug 9, 2003·Science·Chantal ThibertPatrick Mehlen
Jul 20, 2004·Nature Cell Biology·Eiji MatsunagaAlain Chédotal
Aug 4, 2004·Cellular and Molecular Life Sciences : CMLS·P Mehlen, C Thibert
Aug 18, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patrick Mehlen, Eric R Fearon
Sep 3, 2004·Nature·Laetitia MazelinPatrick Mehlen
Nov 16, 2004·Molecular and Cellular Biology·David TulasneVéronique Fafeur
Dec 2, 2004·Nature Reviews. Cancer·Hirofumi Arakawa

❮ Previous
Next ❯

Citations

Feb 25, 2020·ELife·Leslie DuplaquetDavid Tulasne
May 12, 2020·Wiley Interdisciplinary Reviews. Developmental Biology·Amrita PathakBruce D Carter
Mar 1, 2019·Cancers·Arthur AubryMichèle Allouche
Mar 17, 2021·Biochemical Genetics·Diba Borzabadi FarahaniMohammad Reza Fattahi
Apr 23, 2021·Scientific Reports·Ahmad AbdullahHåkan Hedman
Jul 30, 2021·Frontiers in Molecular Neuroscience·Francesco Bedogni, Robert F Hevner
Sep 21, 2021·EMBO Molecular Medicine·Morgan BrissetFrédéric Hollande

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

Related Papers

Bulletin du cancer
Jean-Guy Delcros, Patrick Mehlen
Cell Cycle
Yelena L Pobezinskaya, Zhenggang Liu
© 2022 Meta ULC. All rights reserved